A new polyborate anion, [B7O9(OH)6]3?: Self assembly, XRD and thermal properties of s-fac-[Co(dien)2][B7O9(OH)6]·9H2O

The title compound, s-fac-[Co(dien)2][B7O9(OH)6]·9H2O (1) (dien = HN(CH2CH2NH2)2), has been prepared as a crystalline solid in moderate yield (35%) from the reaction of B(OH)3 with [Co(dien)2][OH]3 in aqueous solution (10:1 ratio). The structure contains a novel polyborate anion [B7O9(OH)6]3 ? which is structurally based on the known ‘ribbon’ isomer of [B7O9(OH)5]2 ?, with an additional [OH]? group coordinated to a B atom in one of the outer boroxole rings. Compound 1 is formed by a self-assembly process in which the cation and anion mutually template themselves from equilibrium mixtures under reaction conditions. The [B7O9(OH)6]3 ? anions are H-bonded to each other in layers with ‘cavities’ suitable for the [Co(dien]2]3 + complex. Three [B7O9(OH)6]3 ? anions are in the secondary coordination sphere (via H-bonds) of each cation, with each anion H-bonded to three cations

Post COVID-19 Guillain-Barre syndrome presents as sensory dominant neuropathy with reversible conduction failure

Guillain-Barré syndrome (GBS) has several clinical variants. The sensory presentations of GBS are atypical but well-recognized. We report a patient who presented with predominantly sensory symptoms associated with reversible conduction failure (RCF). RCF is a well-defined neurophysiological abnormality noted mainly in axonal GBS and may be misinterpreted as evidence of demyelination. A 25-year-old woman presented 2 weeks after a coronavirus 2019 infection with acute sensory symptoms, distal allodynia, mild weakness, and mild hyporeflexia in her upper limbs. A nerve conduction study (NCS) showed delayed motor distal latencies, and lumbar puncture confirmed cytoalbuminologic dissociation. After excluding other etiologies, she was diagnosed with GBS, treated with an IV immunoglobulin course, and showed remarkable recovery. Results of a repeat NCS were consistent with RCF and confirmed the presence of axonal GBS. Increased awareness of sensory GBS and RCF is expected to improve the diagnosis and management of atypical GBS presentations. </p

Two 1-D Coordination Polymers Containing Zinc(II) Hexaborates: [Zn(en){B₆O₇(OH)₆}]·2H₂O (en = 1,2-diaminoethane) and [Zn(pn){B₆O₇(OH)₆}]·1.5H₂O (pn = 1,2-diaminopropane)

The synthesis and characterization by single-crystal X-ray diffraction (XRD) studies of two new zinc(II) hexaborate(2&#8722;) complexes, [Zn(en){B6O7(OH)6}]&#183;2H2O (en = 1,2-diaminoethane) (1) and [Zn(pn){B6O7(OH)6}]&#183;1.5H2O (pn = 1,2-diaminopropane) (2), are reported. These complexes crystallize from aqueous solutions containing 10:1 ratios of B(OH)3 and the appropriate Zn(II) amine complexes ([Zn(en)3][OH]2 or [Zn(pn)3][OH]2) through self-assembly processes. The hexaborate(2&#8722;) anions in 1 and 2 are coordinated to two Zn(II) centers and form one-dimensional (1-D) polymeric coordination chains. R22(8) and R22(6) inter-chain H-bond interactions play an important role in these self-assembly processes and are discussed

Hexaborate(2−) and dodecaborate(6−) anions as ligands to zinc(II) centres: Self-assembly and single-crystal XRD characterization of [Zn{κ3O-B6O7(OH)6}(κ3N-dien)]·0.5H2O (dien = NH(CH2–CH2NH2)2), (NH4)2[Zn{κ2O-B6O7(OH)6}2 (H2O)2]·2H2O and (1,3-pnH2)3[(κ1N-H3N{CH2}3NH2) Zn{κ3O-B12O18(OH)6}]2·14H2O (1,3-pn = 1,3-diaminopropane)

Two zinc(II) hexaborate(2−) complexes, [Zn{κ3O-B6O7(OH)6}(κ3N-dien)]·0.5H2O (dien = NH(CH2CH2NH2)2) (1) and (NH4)2[Zn{κ2O-B6O7(OH)6}2(H2O)2]·2H2O (2), and a zinc(II) dodecaborate(6−) complex, (1,3-pnH2)3[(κ1N-H3N{CH2}3NH2)Zn{κ3O-B12O18(OH)6}]2·14H2O (1,3-pn = 1,3-diaminopropane) (3), have been synthesized and characterized by single-crystal XRD studies. The complexes crystallized through self-assembly processes, from aqueous solutions containing 10:1 ratios of B(OH)3 and appropriate Zn(II) amine complex: [Zn(dien)2](OH)2, [Zn(NH3)4](OH)2, and [Zn(pn)3](OH)2. The hexaborate(2−) anions in 1 and 2 are coordinated to octahedral Zn(II) centres as tridentate (1) or bidentate ligands (2) and the dodecaborate(6−) ligand in 3 is tridentate to a tetrahedral Zn(II) centre

Synthesis and characterization by a single-crystal XRD study of [H₃O]₄[Cu₇(NH₃)₂(H₂O)₄{B₂₄O₃₉(OH)₁₂}]·13H₂O: An unusual [{(H₂O)₂(NH₃)Cu}₂{B₂O₃(OH)₂}₂Cu]²⁺ trimetallic bis(dihydroxytrioxidodiborate) chain supported by a [{Cu₄O}{B₂₀O₃₂(OH)₈}]⁶⁻ cluster

The unusual [Cu7(NH3)2(H2O)4{B24O39(OH)12}]4− cluster anion, isolated in the form of its hydrated hydronium ion salt, has been crystallized in moderate yield (59%) through a templated self-assembly process from [Cu(NH3)4(H2O)2](OH)2 and B(OH)3 (10 equivalents) in aqueous solution. This novel anionic cluster is comprised of two diborate(2-) ligands bridging a linear {Cu3}6+ framework with this Cu3 fragment interacting with, and further supported by, a known larger [{Cu4O}B20O32(OH)8]6− cluster.</p

Copper(2+) complexes of hydroxyoxidopolyborates: Synthesis and characterization of [Cu(MeNHCH₂CH₂NMeH)₂(H₂O)₂][B₅O₆(OH)₄]₂^.2B(OH)₃

The pentaborate(1-) salt, [Cu(dmen)2(H2O)2][B5O6(OH)4]2.2B(OH)3(dmen = N,N′-dimethylethylenediamine, MeHNCH2CH2NHMe), has been synthesized in 48% yield as a crystalline product by reaction of B(OH)3 with [Cu(dmen)2](OH)2]2 (10:1 ratio) in aqueous solution. Single-crystal XRD analysis confirms its ionic structure with one interstitial B(OH)3 per pentaborate(1-) unit. The pentaborate(1-) anions and B(OH)3 molecules are involved in a supramolecular giant H-bonded lattice with B(OH)3 units serving as ‘spacers’ to help accommodate the relatively large [Cu(dmen)2(H2O)2]2+ cations.</p

Two 1-D coordination polymers containing zinc(II) hexaborates: [Zn(en{B6O7(OH)6}]2H2O (en =1,2-diaminoethane) and [Zn(pn{B6O7(OH)6}]1.5H2O (pn = 1,2-diaminopropane)

The synthesis and characterization by single-crystal X-ray diffraction (XRD) studies of two new zinc(II) hexaborate(2&amp;#x100000;) complexes, [Zn(en){B6O7(OH)6}]2H2O (en = 1,2-diaminoethane) (1) and [Zn(pn){B6O7(OH)6}]1.5H2O (pn = 1,2-diaminopropane) (2), are reported. These complexes crystallize from aqueous solutions containing 10:1 ratios of B(OH)3 and the appropriate Zn(II) amine complexes ([Zn(en)3][OH]2 or [Zn(pn)3][OH]2) through self-assembly processes. The hexaborate(2&amp;#x100000;) anions in 1 and 2 are coordinated to two Zn(II) centers and form one-dimensional (1-D) polymeric coordination chains. R22(8) and R22(6) inter-chain H-bond interactions play an important role in these self-assembly processes and are discussed

Favorable outcome of PML‐RARα short isoform and FLT3‐ITD mutation in a patient with several adverse prognostic markers: A case report

Key Clinical Message Complete molecular remission in a “variant APL” patient with short isoform of PML‐RARα and FLT3‐ITD mutation was achieved in response to ATRA and ATO plus IDA instead of standard treatment protocol. The use of FLT3 inhibitor in APL induction management is implicated to prevent differentiation syndrome and coagulopathy experienced in in patients with FLT3‐ITD. Abstract FLT3‐ITD mutations are the most common activating mutations in FLT3 gene, occurring in about 12 to 38% of acute promyelocytic leukemia cases, and are mainly associated with high white blood cell counts and poor clinical outcomes. Here, we present a case of APL variant with adverse prognostic features who showed short isoform [bcr3] of PML‐RARα and FLT3‐ITD mutation at diagnosis. The patient received all‐trans retinoic acid (ATRA) and arsenic trioxide (ATO) plus idarubicin (IDA) instead of standard treatment protocol, and achieved a complete morphological, cytogenetic and molecular response. However, the patient experienced differentiation syndrome, and coagulopathy that was subsequently resolved by continuous oxygen therapy, dexamethasone, and enoxaparin. The use of FLT3 inhibitor in APL induction management is implicated to prevent differentiation syndrome and coagulopathy in patients with FLT3‐ITD mutation